C2i Genomics, a NYC-based company dedicated to improving cancer patient lives and outcomes with a breakthrough tumor pattern recognition approach for liquid biopsy, raised $12m in Series A financing.
The round was led by Casdin Capital and joined by additional new investors including NFX Capital, The Mark Foundation for Cancer Research and other investors.
The company intends to use the funds for the development and clinical validation of its personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers.
Led by Asaf Zviran, co-founder, chief executive officer and chief scientific officer, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The company’s ultra-sensitive liquid biopsy assay will allow physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods.
C2i has an R&D center in Israel.